Chromocell Therapeutics (CHRO) Announces Amendment to Share Buyback Plan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles down after choppy session as investors weigh Hormuz talks
- Meta to pay up to $16.68 billion in mass social media settlement
- Anthropic agrees to $45bn cloud computing deal with Nscale - report
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
Chromocell Announces Amendment to Stock Repurchase Plan
October 24, 2024 8:45 AM EDTFREEHOLD, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (Chromocell, or the Company), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that its board of directors (the Board of Directors) has authorized an amendment (the Amendment) to the Companys existing stock repurchase plan (as amended, the Repurchase Plan) to increase the total value of shares of Chromocells common stock (Common Stock) available for repurchase by the Company under the Repurchase Plan by an additional $500,000, to $750,000.
In addition, the Amendment extends the termination date of the... More
